BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Bruix J, Llovet JM. Prognostic assessment and evaluation of the benefits of treatment. J Clin Gastroenterol. 2002;35:S138-S142. [PMID: 12394217 DOI: 10.1097/00004836-200211002-00010] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 1.3] [Reference Citation Analysis]
Number Citing Articles
1 Cho CS, Gonen M, Shia J, Kattan MW, Klimstra DS, Jarnagin WR, D’Angelica MI, Blumgart LH, DeMatteo RP. A novel prognostic nomogram is more accurate than conventional staging systems for predicting survival after resection of hepatocellular carcinoma. J Am Coll Surg. 2008;206:281-291. [PMID: 18222381 DOI: 10.1016/j.jamcollsurg.2007.07.031] [Cited by in Crossref: 83] [Cited by in F6Publishing: 83] [Article Influence: 5.5] [Reference Citation Analysis]
2 Lau WY, Yu SC, Lai EC, Leung TW. Transarterial chemoembolization for hepatocellular carcinoma. J Am Coll Surg. 2006;202:155-168. [PMID: 16377509 DOI: 10.1016/j.jamcollsurg.2005.06.263] [Cited by in Crossref: 52] [Cited by in F6Publishing: 47] [Article Influence: 3.1] [Reference Citation Analysis]
3 Kettenbach J, Stadler A, Katzler IV, Schernthaner R, Blum M, Lammer J, Rand T. Drug-loaded microspheres for the treatment of liver cancer: review of current results. Cardiovasc Intervent Radiol. 2008;31:468-476. [PMID: 18228095 DOI: 10.1007/s00270-007-9280-6] [Cited by in Crossref: 112] [Cited by in F6Publishing: 91] [Article Influence: 8.0] [Reference Citation Analysis]
4 Jang JW, Choi JY, Bae SH, Kim CW, Yoon SK, Cho SH, Yang JM, Ahn BM, Lee CD, Lee YS, Chung KW, Sun HS. Transarterial chemo-lipiodolization can reactivate hepatitis B virus replication in patients with hepatocellular carcinoma. J Hepatol. 2004;41:427-435. [PMID: 15336446 DOI: 10.1016/j.jhep.2004.05.014] [Cited by in Crossref: 87] [Cited by in F6Publishing: 82] [Article Influence: 5.1] [Reference Citation Analysis]
5 Guan M, Zhou Y, Zhu QL, Liu Y, Bei YY, Zhang XN, Zhang Q. N-trimethyl chitosan nanoparticle-encapsulated lactosyl-norcantharidin for liver cancer therapy with high targeting efficacy. Nanomedicine 2012;8:1172-81. [PMID: 22321383 DOI: 10.1016/j.nano.2012.01.009] [Cited by in Crossref: 53] [Cited by in F6Publishing: 50] [Article Influence: 5.3] [Reference Citation Analysis]
6 Zhang CG, Zhu QL, Zhou Y, Liu Y, Chen WL, Yuan ZQ, Yang SD, Zhou XF, Zhu AJ, Zhang XN, Jin Y. N-Succinyl-chitosan nanoparticles coupled with low-density lipoprotein for targeted osthole-loaded delivery to low-density lipoprotein receptor-rich tumors. Int J Nanomedicine 2014;9:2919-32. [PMID: 24966673 DOI: 10.2147/IJN.S59799] [Cited by in Crossref: 24] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
7 Kiely JM, Rilling WS, Touzios JG, Hieb RA, Franco J, Saeian K, Quebbeman EJ, Pitt HA. Chemoembolization in Patients at High Risk: Results and Complications. Journal of Vascular and Interventional Radiology 2006;17:47-53. [DOI: 10.1097/01.rvi.0000195074.43474.2f] [Cited by in Crossref: 37] [Cited by in F6Publishing: 11] [Article Influence: 2.3] [Reference Citation Analysis]
8 Biondi A, Malaguarnera G, Vacante M, Berretta M, D’Agata V, Malaguarnera M, Basile F, Drago F, Bertino G. Elevated serum levels of Chromogranin A in hepatocellular carcinoma. BMC Surg. 2012;12 Suppl 1:S7. [PMID: 23173843 DOI: 10.1186/1471-2482-12-s1-s7] [Cited by in Crossref: 23] [Cited by in F6Publishing: 15] [Article Influence: 2.3] [Reference Citation Analysis]
9 Armeanu S, Pathil A, Venturelli S, Mascagni P, Weiss TS, Göttlicher M, Gregor M, Lauer UM, Bitzer M. Apoptosis on hepatoma cells but not on primary hepatocytes by histone deacetylase inhibitors valproate and ITF2357. Journal of Hepatology 2005;42:210-7. [DOI: 10.1016/j.jhep.2004.10.020] [Cited by in Crossref: 70] [Cited by in F6Publishing: 70] [Article Influence: 4.1] [Reference Citation Analysis]
10 Testa R, Testa E, Giannini E, Botta F, Malfatti F, Chiarbonello B, Fumagalli A, Polegato S, Podesta E, Romagnoli P. Trans-catheter arterial chemoembolisation for hepatocellular carcinoma in patients with viral cirrhosis: role of combined staging systems, Cancer Liver Italian Program (CLIP) and Model for End-stage Liver Disease (MELD), in predicting outcome after treatment. Aliment Pharmacol Ther. 2003;17:1563-1569. [PMID: 12823161 DOI: 10.1046/j.1365-2036.2003.01647.x] [Cited by in Crossref: 42] [Cited by in F6Publishing: 40] [Article Influence: 2.2] [Reference Citation Analysis]
11 Vongchan P, Wutti-In Y, Sajomsang W, Gonil P, Kothan S, Linhardt RJ. N,N,N-Trimethyl chitosan nanoparticles for the delivery of monoclonal antibodies against hepatocellular carcinoma cells. Carbohydr Polym 2011;85:215-20. [PMID: 21552341 DOI: 10.1016/j.carbpol.2011.02.018] [Cited by in Crossref: 31] [Cited by in F6Publishing: 25] [Article Influence: 2.8] [Reference Citation Analysis]
12 Mazzoccoli G, Tarquini R, Valoriani A, Oben J, Vinciguerra M, Marra F. Management strategies for hepatocellular carcinoma: old certainties and new realities. Clin Exp Med 2016;16:243-56. [PMID: 26077653 DOI: 10.1007/s10238-015-0368-z] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 2.3] [Reference Citation Analysis]
13 Ramesh V, Ganesan K. Integrative functional genomic analysis unveils the differing dysregulated metabolic processes across hepatocellular carcinoma stages. Gene 2016;588:19-29. [PMID: 27107678 DOI: 10.1016/j.gene.2016.04.039] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
14 Di-Wen S, Pan GZ, Hao L, Zhang J, Xue QZ, Wang P, Yuan QZ. Improved antitumor activity of epirubicin-loaded CXCR4-targeted polymeric nanoparticles in liver cancers. Int J Pharm 2016;500:54-61. [PMID: 26748365 DOI: 10.1016/j.ijpharm.2015.12.066] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 3.1] [Reference Citation Analysis]
15 Sung PS, Bae SH, Jang JW, Song DS, Kim HY, Yoo SH, Park CH, Kwon JH, Song MJ, You CR, Choi JY, Yoon SK. Differences in the patterns and outcomes of enhanced viral replication between hepatitis C virus and hepatitis B virus in patients with hepatocellular carcinoma during transarterial chemolipiodolization. Korean J Hepatol 2011;17:299-306. [PMID: 22310794 DOI: 10.3350/kjhep.2011.17.4.299] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
16 El-Zayadi AR, Badran HM, Shawky S, Emara S, El-Bareedy A, Sobhi M. Effect of surveillance for hepatocellular carcinoma on tumor staging and treatment decisions in Egyptian patients. Hepatol Int 2010;4:500-6. [PMID: 20827407 DOI: 10.1007/s12072-010-9170-x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
17 Seo YS, Kim YJ, Um SH, Yoo H, Lee JW, Kim YS, Jeen YT, Chun HJ, Kim CD, Ryu HS. Evaluation of the prognostic powers of various tumor status grading scales in patients with hepatocellular carcinoma. J Gastroenterol Hepatol. 2008;23:1267-1275. [PMID: 18637054 DOI: 10.1111/j.1440-1746.2008.05480.x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 0.7] [Reference Citation Analysis]
18 Maksan SM, Schmidt E, Ryschich E, Harms W, Schmidt J. Enhancement of leukocyte adhesion after percutaneous irradiation in rats with hepatocellular carcinoma. World J Gastroenterol 2005; 11(13): 1991-1994 [PMID: 15800992 DOI: 10.3748/wjg.v11.i13.1991] [Reference Citation Analysis]
19 Simioni C, Cani A, Martelli AM, Zauli G, Alameen AA, Ultimo S, Tabellini G, McCubrey JA, Capitani S, Neri LM. The novel dual PI3K/mTOR inhibitor NVP-BGT226 displays cytotoxic activity in both normoxic and hypoxic hepatocarcinoma cells. Oncotarget 2015;6:17147-60. [PMID: 26003166 DOI: 10.18632/oncotarget.3940] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 4.3] [Reference Citation Analysis]
20 Szalay F, Hantos MB, Horvath A, Lakatos PL, Folhoffer A, Dunkel K, Hegedus D, Tekes K. Increased nociceptin/orphanin FQ plasma levels in hepatocellular carcinoma. World J Gastroenterol 2004; 10(1): 42-45 [PMID: 14695766 DOI: 10.3748/wjg.v10.i1.42] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 14] [Article Influence: 0.9] [Reference Citation Analysis]
21 Molinari M, Helton S. Hepatic resection versus radiofrequency ablation for hepatocellular carcinoma in cirrhotic individuals not candidates for liver transplantation: a Markov model decision analysis. Am J Surg. 2009;198:396-406. [PMID: 19520354 DOI: 10.1016/j.amjsurg.2009.01.016] [Cited by in Crossref: 54] [Cited by in F6Publishing: 51] [Article Influence: 4.2] [Reference Citation Analysis]
22 Arunraj TR, Sanoj Rejinold N, Ashwin Kumar N, Jayakumar R. Bio-responsive chitin-poly(L-lactic acid) composite nanogels for liver cancer. Colloids Surf B Biointerfaces 2014;113:394-402. [PMID: 24129331 DOI: 10.1016/j.colsurfb.2013.09.023] [Cited by in Crossref: 30] [Cited by in F6Publishing: 26] [Article Influence: 3.3] [Reference Citation Analysis]
23 Cercueil J, Ferrant E, Isambert N, Jouve J, Flesch M, Krause D, Bedenne L, Chauffert B. Réponse majeure d’un volumineux carcinome hépatocellulaire à une chimioembolisation par pirarubicine, amiodarone et Lipiodol®. Gastroentérologie Clinique et Biologique 2004;28:1281-3. [DOI: 10.1016/s0399-8320(04)95221-9] [Cited by in Crossref: 3] [Article Influence: 0.2] [Reference Citation Analysis]